Working… Menu

Study of Efficacy, Safety and Tolerability of CMK389 in Patients With Chronic Pulmonary Sarcoidosis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT04064242
Recruitment Status : Recruiting
First Posted : August 21, 2019
Last Update Posted : May 7, 2021
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals )

Brief Summary:
The purpose of this proof of concept study is to determine whether CMK389 displays the safety and efficacy profile to support further development in chronic pulmonary sarcoidosis.

Condition or disease Intervention/treatment Phase
Pulmonary Sarcoidosis Drug: CMK389 Drug: Placebo Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 66 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: Participants will be assigned to one of two treatment arms, either CMK389 or placebo.
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Subject and Investigator Blinded, Randomized, Placebo-controlled, Repeat-dose, Multicenter Study to Investigate Efficacy, Safety, and Tolerability of CMK389 in Patients With Chronic Pulmonary Sarcoidosis
Actual Study Start Date : September 23, 2020
Estimated Primary Completion Date : December 20, 2022
Estimated Study Completion Date : March 13, 2023

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Sarcoidosis

Arm Intervention/treatment
Experimental: CMK389
Drug: CMK389
single i.v. dose every 4 weeks

Placebo Comparator: Placebo
Drug: Placebo
single i.v. dose every 4 weeks

Primary Outcome Measures :
  1. Forced Vital Capacity [ Time Frame: Baseline to Week 16 ]
    Change in forced vital capacity, % of predicted, between CMK389 and placebo.

Secondary Outcome Measures :
  1. Composite index of pulmonary physiology and exercise capacity [ Time Frame: Baseline to Week 16 ]
    Relative reduction in forced volume capacity ≥ 10% or relative reduction in forced expiratory volume in one second ≥ 10% or relative reduction of diffusion capacity ≥ 15% or relative reduction of 6-minute walk distance ≥ 50 meters.

  2. [18F]-fluorodeoxyglucose positron emission tomography/computed tomography [ Time Frame: Baseline to Week 16 ]
    Change in imaging maximum standardized uptake value and mean standardized uptake value.

  3. Pulmonary physiology [ Time Frame: Baseline to Week 16 ]
    Change in forced expiratory volume in one second and diffusion capacity for carbon monoxide.

  4. Steroid use (mg days) [ Time Frame: Baseline to Week 16 ]
    Difference in steroid usage for each arm of the study.

  5. Exercise capacity [ Time Frame: Baseline to Week 16 ]
    Change in 6-minute walk distance.

  6. Pharmacokinetics of CMK389 maximum concentration (Cmax) [ Time Frame: Day 1 through Week 28 ]
    The observed maximum plasma concentration (Cmax/end of infusion) [mass / volume].

  7. Pharmacokinetics of CMK389 trough concentration (Ctrough) [ Time Frame: Day 1 through Week 28 ]
    The lowest concentration of drug (Ctrough) reached before the next dose is administered.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Subjects must have a body mass index (BMI) at screening within the range of 18 - 43 kg/m2. BMI = Body weight (kg) / [Height (m)]2
  • Biopsy proven pulmonary sarcoidosis diagnosed > 1 year prior to screening
  • Scadding stage II, III or IV as determined by the most recent chest x-ray obtained within 12 months prior to screening or at screening (confirmed by the Investigator)
  • HRCT extent of fibrosis <15% (confirmed by the central imaging reader) at screening
  • Treatment with 5-15 mg/day prednisone (or prednisone oral equivalents) for ≥ 6 months prior to screening.
  • Co-medication with methotrexate or azathioprine for ≥ 6 months prior to screening (Note: hydroxychloroquine is allowed as background therapy but not required)
  • Able to perform reliable, reproducible pulmonary function test maneuvers per American Thoracic Society/European Respiratory Society (ATS/ERS) guidelines

Exclusion Criteria:

  • Diagnosis of significant pulmonary hypertension (WHO group 5) requiring pharmacological treatment
  • A known diagnosis of cardiac sarcoidosis
  • A known diagnosis of neurosarcoidosis
  • Forced vital capacity (FVC) <50% of predicted at screening (central read)
  • Modified British Medical Research Council (mMRC) dyspnea scale ≥ 3 at screening
  • Concomitant treatment with leflunomide, cyclophosphamide, mycophenolate, infliximab, etanercept, adalimumab, golimumab, ustekinumab, roflumilast, pentoxifylline, and abatacept within 12 weeks of screening
  • Prior treatment with rituximab, canakinumab, anakinra, and tocilizumab
  • Current smokers, defined as inhaled use of tobacco products
  • Any conditions or significant medical problems which in the opinion of the investigator and in consultation with the sponsor, immunocompromises the patient and/or places the patient at unacceptable risk for immunomodulatory therapy
  • Contraindication to FDG-PET scan investigations such as severe claustrophobia or uncontrolled diabetes
  • History or current diagnosis of ECG abnormalities indicating significant risk of safety for patients participating in the study
  • A diagnosis of Lofgren's syndrome
  • A history of pancreatitis
  • Other protocol-defined inclusion/exclusion criteria may apply

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT04064242

Layout table for location contacts
Contact: Novartis Pharmaceuticals 1-888-669-6682
Contact: Novartis Pharmaceuticals +41613241111

Layout table for location information
United States, Florida
Novartis Investigative Site Recruiting
Gainesville, Florida, United States, 32610
United States, Maryland
Novartis Investigative Site Recruiting
Baltimore, Maryland, United States, 21224
United States, Ohio
Novartis Investigative Site Recruiting
Cincinnati, Ohio, United States, 45267
Novartis Investigative Site Recruiting
Brno Bohunice, Czechia, 625 00
Novartis Investigative Site Recruiting
Olomouc, Czechia, 775 20
Novartis Investigative Site Recruiting
Aarhus N, Denmark, 8200
Novartis Investigative Site Recruiting
Odense C, Denmark, DK 5000
Novartis Investigative Site Recruiting
Heidelberg, Baden-Württemberg, Germany, 69126
Novartis Investigative Site Recruiting
Essen, Germany, 45147
Novartis Investigative Site Recruiting
Frankfurt, Germany, 60596
Novartis Investigative Site Recruiting
Hamburg, Germany, 20246
Novartis Investigative Site Recruiting
Hannover, Germany, 30625
Novartis Investigative Site Recruiting
Bialystok, Poland, 15-044
Novartis Investigative Site Recruiting
Lodz, Poland, 90 153
Sponsors and Collaborators
Novartis Pharmaceuticals
Layout table for additonal information
Responsible Party: Novartis Pharmaceuticals Identifier: NCT04064242    
Other Study ID Numbers: CCMK389X2201
First Posted: August 21, 2019    Key Record Dates
Last Update Posted: May 7, 2021
Last Verified: May 2021

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Novartis ( Novartis Pharmaceuticals ):
chronic pulmonary sarcoidosis
Additional relevant MeSH terms:
Layout table for MeSH terms
Sarcoidosis, Pulmonary
Lymphoproliferative Disorders
Lymphatic Diseases
Lung Diseases, Interstitial
Lung Diseases
Respiratory Tract Diseases